Researchers in Australia conducted a systematic analysis of several randomized control trials that evaluated weight loss as an intervention for breast, endometrial, and ovarian cancer.
Several studies have demonstrated that obesity can reduce survival in cancer patients. While definitive trials that include weight loss as an adjuvant intervention have not yet been conducted, several observational studies have evaluated the impact of this intervention on survival in women with breast and other cancers. Researchers in Australia conducted a systematic analysis of several randomized control trials that evaluated weight loss as an intervention for breast, endometrial, and ovarian cancer.
The authors screened articles in PubMed and Web of Science, published between 2013 and July 2016. Of the total 311 publications identified, 10 were considered eligible for analysis—6 were in breast cancer survivors and 2 in endometrial cancer. Women were recruited to participated anytime between 9.4 months to up to 4 to 5 years following diagnosis. Interventions included diet and exercise, but the method of delivery and duration of the intervention varied. Interventions included:
Based on their analysis, the researchers found that while weight control and lifestyle changes are important in survivorship care, the biggest challenge is to maintain participant motivation and engagement at the end of the intervention to continue their weight-loss regimen. The other challenge with these studies, the authors wrote, is their “one-size-fits-all” approach with respect to intervention delivery, targets, and the content, which could make the intervention ineffective. The authors believe that researchers need to develop a more personalized approach to weight loss and lifestyle interventions.
Additional research conducted by these authors by mining ongoing trials, on ClinicalTrials.org and the International Standard Randomized Controlled Trial Number Registry, identified several ongoing randomized controlled clinical trials, which they believe “will potentially provide definitive assessment on whether weight loss can improve clinical outcome in female cancer survivors.”
Reference
Chlebowski RT, Reeves MM. Weight loss randomized intervention trials in female cancer survivors. J Clin Oncol. 2016;34(35):4238-4248. doi: 10.1200/JCO.2016.69.4026.
Real-World Study Reveals Key Insights into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Many Patients With Psoriasis in Clinical Trials Experience Nocebo Effects, Study Finds
April 18th 2024Half of patients exposed to placebo in clinical trials experienced adverse events (AEs), which may be partially explainable by nocebo effects, according to a recent review and meta-analysis.
Read More
Low-Volume Hospitals Had Higher Reoperation Rate, Postoperative Complications in CRC
April 18th 2024Patients opting for elective colorectal surgery to address colorectal cancer (CRC) could have different rates of reoperation and postoperative complications based on the size of the hospital.
Read More